555 related articles for article (PubMed ID: 28288964)
1. IL-38 overexpression induces anti-inflammatory effects in mice arthritis models and in human macrophages in vitro.
Boutet MA; Najm A; Bart G; Brion R; Touchais S; Trichet V; Layrolle P; Gabay C; Palmer G; Blanchard F; Le Goff B
Ann Rheum Dis; 2017 Jul; 76(7):1304-1312. PubMed ID: 28288964
[TBL] [Abstract][Full Text] [Related]
2. Complementary action of granulocyte macrophage colony-stimulating factor and interleukin-17A induces interleukin-23, receptor activator of nuclear factor-κB ligand, and matrix metalloproteinases and drives bone and cartilage pathology in experimental arthritis: rationale for combination therapy in rheumatoid arthritis.
van Nieuwenhuijze AE; van de Loo FA; Walgreen B; Bennink M; Helsen M; van den Bersselaar L; Wicks IP; van den Berg WB; Koenders MI
Arthritis Res Ther; 2015 Jun; 17(1):163. PubMed ID: 26081345
[TBL] [Abstract][Full Text] [Related]
3. Mast cell activation and its relation to proinflammatory cytokine production in the rheumatoid lesion.
Woolley DE; Tetlow LC
Arthritis Res; 2000; 2(1):65-74. PubMed ID: 11219391
[TBL] [Abstract][Full Text] [Related]
4. Expression of interleukin-21 receptor, but not interleukin-21, in synovial fibroblasts and synovial macrophages of patients with rheumatoid arthritis.
Jüngel A; Distler JH; Kurowska-Stolarska M; Seemayer CA; Seibl R; Forster A; Michel BA; Gay RE; Emmrich F; Gay S; Distler O
Arthritis Rheum; 2004 May; 50(5):1468-76. PubMed ID: 15146416
[TBL] [Abstract][Full Text] [Related]
5. Protection against cartilage and bone destruction by systemic interleukin-4 treatment in established murine type II collagen-induced arthritis.
Joosten LA; Lubberts E; Helsen MM; Saxne T; Coenen-de Roo CJ; Heinegård D; van den Berg WB
Arthritis Res; 1999; 1(1):81-91. PubMed ID: 11056663
[TBL] [Abstract][Full Text] [Related]
6. Activated protein C targets immune cells and rheumatoid synovial fibroblasts to prevent inflammatory arthritis in mice.
Xue M; Dervish S; McKelvey KJ; March L; Wang F; Little CB; Jackson CJ
Rheumatology (Oxford); 2019 Oct; 58(10):1850-1860. PubMed ID: 30649471
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-20 antibody is a potential therapeutic agent for experimental arthritis.
Hsu YH; Chang MS
Arthritis Rheum; 2010 Nov; 62(11):3311-21. PubMed ID: 20722035
[TBL] [Abstract][Full Text] [Related]
8. Interactions between IL-32 and tumor necrosis factor alpha contribute to the exacerbation of immune-inflammatory diseases.
Shoda H; Fujio K; Yamaguchi Y; Okamoto A; Sawada T; Kochi Y; Yamamoto K
Arthritis Res Ther; 2006; 8(6):R166. PubMed ID: 17078892
[TBL] [Abstract][Full Text] [Related]
9. [The effect and mechanism of transient receptor potential M(2) in antigen-induced arthritis mice].
Li MY; Zhao Y; Luo YB; Li YH; Liu Y
Zhonghua Nei Ke Za Zhi; 2019 Dec; 58(12):911-914. PubMed ID: 31775456
[TBL] [Abstract][Full Text] [Related]
10. IL-17B and IL-17C are associated with TNF-alpha production and contribute to the exacerbation of inflammatory arthritis.
Yamaguchi Y; Fujio K; Shoda H; Okamoto A; Tsuno NH; Takahashi K; Yamamoto K
J Immunol; 2007 Nov; 179(10):7128-36. PubMed ID: 17982105
[TBL] [Abstract][Full Text] [Related]
11. Increased synovial expression of IL-27 by IL-17 in rheumatoid arthritis.
Baek SH; Lee SG; Park YE; Kim GT; Kim CD; Park SY
Inflamm Res; 2012 Dec; 61(12):1339-45. PubMed ID: 22825627
[TBL] [Abstract][Full Text] [Related]
12. Semaphorin 4D Contributes to Rheumatoid Arthritis by Inducing Inflammatory Cytokine Production: Pathogenic and Therapeutic Implications.
Yoshida Y; Ogata A; Kang S; Ebina K; Shi K; Nojima S; Kimura T; Ito D; Morimoto K; Nishide M; Hosokawa T; Hirano T; Shima Y; Narazaki M; Tsuboi H; Saeki Y; Tomita T; Tanaka T; Kumanogoh A
Arthritis Rheumatol; 2015 Jun; 67(6):1481-90. PubMed ID: 25707877
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-19 blockade attenuates collagen-induced arthritis in rats.
Hsu YH; Hsieh PP; Chang MS
Rheumatology (Oxford); 2012 Mar; 51(3):434-42. PubMed ID: 21719423
[TBL] [Abstract][Full Text] [Related]
14. Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion.
Lubberts E; Koenders MI; Oppers-Walgreen B; van den Bersselaar L; Coenen-de Roo CJ; Joosten LA; van den Berg WB
Arthritis Rheum; 2004 Feb; 50(2):650-9. PubMed ID: 14872510
[TBL] [Abstract][Full Text] [Related]
15. CARD11 blockade suppresses murine collagen-induced arthritis via inhibiting CARD11/Bcl10 assembly and T helper type 17 response.
Wang H; Zhao J; Zhang H; Huang Y; Wang S; Tu Q; Yang N
Clin Exp Immunol; 2014 May; 176(2):238-45. PubMed ID: 24443940
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-10 attenuation of collagen-induced arthritis is associated with suppression of interleukin-17 and retinoid-related orphan receptor γt production in macrophages and repression of classically activated macrophages.
Ye L; Wen Z; Li Y; Chen B; Yu T; Liu L; Zhang J; Ma Y; Xiao S; Ding L; Li L; Huang Z
Arthritis Res Ther; 2014 Apr; 16(2):R96. PubMed ID: 24742125
[TBL] [Abstract][Full Text] [Related]
17. IL-37 Alleviates Rheumatoid Arthritis by Suppressing IL-17 and IL-17-Triggering Cytokine Production and Limiting Th17 Cell Proliferation.
Ye L; Jiang B; Deng J; Du J; Xiong W; Guan Y; Wen Z; Huang K; Huang Z
J Immunol; 2015 Jun; 194(11):5110-9. PubMed ID: 25917106
[TBL] [Abstract][Full Text] [Related]
18. IL-17/Th17 mediated synovial inflammation is IL-22 independent.
van Hamburg JP; Corneth OB; Paulissen SM; Davelaar N; Asmawidjaja PS; Mus AM; Lubberts E
Ann Rheum Dis; 2013 Oct; 72(10):1700-7. PubMed ID: 23328939
[TBL] [Abstract][Full Text] [Related]
19. Joint production of IL-22 participates in the initial phase of antigen-induced arthritis through IL-1β production.
Pinto LG; Talbot J; Peres RS; Franca RF; Ferreira SH; Ryffel B; Aves-Filho JC; Figueiredo F; Cunha TM; Cunha FQ
Arthritis Res Ther; 2015 Sep; 17(1):235. PubMed ID: 26330334
[TBL] [Abstract][Full Text] [Related]
20. Interleukin 17 (IL-17) increases the expression of Toll-like receptor-2, 4, and 9 by increasing IL-1beta and IL-6 production in autoimmune arthritis.
Lee JH; Cho ML; Kim JI; Moon YM; Oh HJ; Kim GT; Ryu S; Baek SH; Lee SH; Kim HY; Kim SI
J Rheumatol; 2009 Apr; 36(4):684-92. PubMed ID: 19228664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
